References
- Venugopal V, Pavlakis S. Duchenne muscular dystrophy. 2022.
- Yao S, Chen Z, Yu Y, et al. Current pharmacological strategies for Duchenne muscular dystrophy. Front Cell Dev Biol. 2021;9:689533.
- Emery AEH. The muscular dystrophies. Lancet. 2002;359(9307):687–695. Elsevier B.V.
- Mohamadian M, Rastegar M, Pasamanesh N, et al. Clinical and molecular spectrum of muscular dystrophies (MDs) with intellectual disability (id): a comprehensive overview. J Mol Neurosci. 2022;72(1):9–23. Humana Press Inc.
- Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim Biophys Acta. 2014;1838(2):635–642.
- Grounds MD, Terrill JR, Al-Mshhdani BA, et al. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. Dis Model Mech. 2020;13(2).
- Tulangekar A, Sztal TE, Lawler SE. Inflammation in Duchenne muscular dystrophy-Exploring the role of neutrophils in muscle damage and regeneration. Biomedicines. 2021;10(1):9.
- Klingler W, Jurkat-Rott K, Lehmann-Horn F, et al. The role of fibrosis in Duchenne muscular dystrophy. Acta Myol. 2012;31(3):184–195.
- Crisafulli S, Sultana J, Fontana A, et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020 BioMed Central Ltd; 151: 10.1186/s13023-020-01430-8
- Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013;56(6):443–454.
- Broomfield J, Hill M, Guglieri M, et al. Life expectancy in Duchenne muscular dystrophy. Neurology. 2021;97(23):E2304–E2314.
- Szabo SM, Salhany RM, Deighton A, et al. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021 BioMed Central Ltd; 161: 10.1186/s13023-021-01862-w
- Florczyk-Soluch U, Polak K, Dulak J. The multifaceted view of heart problem in Duchenne muscular dystrophy. Cell Mol Life Sci. 2021;78(14):5447–5468.
- Kutluk MG, Doğan ÇS. Kidney involvement and associated risk factors in children with Duchenne muscular dystrophy. Pediatr Nephrol. 2020;35(10):1953–1958.
- Uttley L, Carlton J, Woods HB, et al. A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. Health Qual Life Outcomes. 2018;16(1):237.
- Landfeldt E, Edström J, Buccella F, et al. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987–996. Blackwell Publishing Ltd.
- Landfeldt E, Lindgren P, Bell CF, et al. The burden of Duchenne muscular dystrophy an international, cross-sectional study. 2014.
- Kourakis S, Timpani CA, Campelj DG, et al. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis. 2021;16(1). DOI: 10.1186/s13023-021-01758-9
- Koeks Z, Bladen CL, Salgado D, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database. J Neuromuscul Dis. 2017;4(4):293–306.
- McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–461.
- Bushby K, Finkel R, Birnkrant DJ, et al. Review diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. 2010;77.
- Gloss D, Moxley Iii RT, Ashwal S, et al. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy. 2016.
- Quattrocelli M, Zelikovich AS, Salamone IM, et al. Mechanisms and clinical applications of glucocorticoid steroids in muscular dystrophy. J Neuromuscul Dis. 2021;8(1):39–52. IOS Press BV.
- Traynor K. Deflazacort approved for Duchenne muscular dystrophy. Am J Health Syst Pharm. 2017;74(6):368.
- Nayak S, Acharjya B. Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2008;53(4):167–170.
- Prednisone [package insert]. Columbus OH: Roxane Laboratories, Inc.; 2012.
- Emflaza [package insert]. Northbrook IL: Marathon Pharmaceuticals, LLC; 2017.
- Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294.
- Griggs RC, Phillip Miller Cheryl Greenberg JR, Fehlings DL Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. 2016.
- McDonald CM, Sajeev G, Yao Z, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61(1):26–35.
- Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study [Internet]. 2015. Available from: www.for-dmd.org.
- Guglieri M, Bushby K, McDermott MP, et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy. JAMA Internet]. 2022;327:1456. Available from.;(15):.: https://jamanetwork.com/journals/jama/fullarticle/2790925.
- Kochar GS, Sondhi V, Kabra SK, et al. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: a randomized, open-label trial. Muscle Nerve. 2022;65(1):60–66.
- Reddy C, Patil AN, Suthar R, et al. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): a randomized, double-blind non-inferiority trial. Eur J Paediatr Neurol. 2022;38:77–84.
- Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019;2(1).
- Mah JK, Clemens PR, Guglieri M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-Month nonrandomized controlled open-Label extension trial. JAMA Network Open. 2022;5(1):e2144178.
- Vamorolone IP. Filing for FDA approval for DMD expected by June [Internet]. 2022 [cited 2022 Jul 6]. Available from: https://musculardystrophynews.com/news/santhera-reveragen-start-fda-application-seeking-approval-vamorolone-dmd/.
- Finkel RS, Finanger E, Vandenborne K, et al. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: results of the MoveDMD phase 2 and open label extension trial. Neuromuscul Disord. 2021;31(5):385–396.
- Finkel RS, McDonald CM, Lee Sweeney H, et al. A randomized, Double-Blind, Placebo-Controlled, global Phase 3 study of edasalonexent in pediatric patients with Duchenne muscular dystrophy: results of the polarisDMD trial. J Neuromuscul Dis. 2021;8(5):769–784.
- Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000.
- Komaki H, Maegaki Y, Matsumura T, et al. Early phase 2 trial of Tas-205 in patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020;7(2):181–190.
- Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. 2020;27(9):407–416. Springer Nature.
- Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36(4): 395–402.
- Exondys 51 [package insert]. Cambridge MA: Sarepta Therapeutics, Inc.; 2016.
- Silverman E. Sarepta to charge $300K for Duchenne drug. “We tried to be reasonable,” CEO says. 2016 [cited 2022 Jun 30]; Available from: https://www.statnews.com/pharmalot/2016/09/19/sarepta-duchenne-drug-prices/.
- Alfano LN, Charleston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (Baltimore). 2019;98(26):e15858.
- Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637–647.
- Califf RM. Center for drug evaluation and research. 2016 [cited 2022 Jun 21]; Available from: https://www.accessdata.fda.gov/drug satfda_docs/nda/2016/206488_summaryreview_Redacted.pdf.
- McDonald CM, Shieh PB, Abdel-Hamid HZ, et al. Open-Label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J Neuromuscul Dis. 2021;8(6):989–1001.
- Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257–271.
- Vyondys 53 [package insert]. Cambridge MA: Sarepta Therapeutics, Inc.; 2019.
- Vyondys FM. 53 available to Duchenne patients in the US. 2019 [cited 2022 Jun 29]; Available from: https://musculardystrophynews.com/news/vyondys-53-available-duchenne-patients-in-the-us/.
- Vinluan F, Flags FDA. Risk of infection, kidney damage for Sarepta Duchenne drugs. 2020 [cited 2022 Jun 29]; Available from: https://xconomy.com/boston/2020/01/22/fda-flags-risk-of-infection-kidney-damage-for-sarepta-duchenne-drugs/.
- Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270–e2282.
- Viltepso [package insert]. Paramus NJ: NS Pharma, Inc.; 2020.
- Fidler B. FDA gives speedy approval to another Duchenne drug. 2020 [cited 2022 Jun 30]; Available from: https://www.biopharmadive.com/news/viltolarsen-duchenne-fda-approval-ns-pharma/583410/.
- Komaki H, Takeshima Y, Matsumura T, et al. Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1/2 study. Ann Clin Transl Neurol. 2020;7(12):2393–2408.
- Amondys 45 [package insert]. Cambridge MA: Sarepta Therapeutics, Inc.; 2021.
- Terry M. FDA Approves Third Sarepta treatment for Duchenne muscular dystrophy. 2021 [cited 2022 Jun 30]; Available from: https://www.biospace.com/article/fda-greenlights-sarepta-s-amondys-45-for-duchenne-muscular-dystrophy/.
- FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [Internet]. 2016 [cited 2022 Jul 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy.
- FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2020 [cited 2022 Jul 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation.
- FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2019 [cited 2022 Jul 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation.
- FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2021 [cited 2022 Jul 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0.
- Agboola F. The effectiveness and value of deflazacort and exon-skipping [Internet]. 2020. Available from: https://icer-review.org/pro-.
- Aartsma-Rus A, Morgan J, Lonkar P, et al. Report of a TREAT-NMD/World Duchenne organisation meeting on dystrophin quantification methodology. J Neuromuscul Dis. 2019;6(1):147–159. IOS Press.
- Wells DJ. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy? J Muscle Res Cell Motil. 2019;40(2):141–150.
- Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44(14):6518–6548.
- Wexler M. SRP-5051. 2022 [cited 2022 Jun 22]; Available from: https://musculardystrophynews.com/srp-5051/.
- Sarepta therapeutics provides update on SRP-5051 for the treatment of Duchenne muscular dystrophy [Internet]. 2022 [cited 2022 Jul 6]. Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne.
- Wexler M. Exon 45 skipping therapy for DMD shows safety in small trial. 2021 [cited 2022 Jul 4]; Available from: https://musculardystrophynews.com/news/ds-5141-shows-promise-in-small-dmd-clinical-trial/.
- Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163–R172. Oxford University Press.
- Wexler M. Wave life sciences discontinues development of suvodirsen for DMD. 2019 Dec 17 [cited 2022 Jun 22]; Available from: https://musculardystrophynews.com/news/wave-life-sciences-discontinues-suvodirsen-development-for-dmd/.
- Arif M. Results from Italfarmaco’s EPIDYS trial. 2022 [cited 2022 Jul 4]; Available from: https://www.actionduchenne.org/results-from-italfarmacos-epidys-trial/?utm_source=rss&utm_medium=rss&utm_campaign=results-from-italfarmacos-epidys-trial.
- Shawi F, Perras C, Severn M, et al. Emerging drugs for Duchenne muscular dystrophy. 2016.
- Bettica P, Petrini S, D’Oria V, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(10):643–649.
- Mccormack K. HOPE for patients with a muscle destroying disease. 2022 [cited 2022 Jul 4]; Available from: https://blog.cirm.ca.gov/tag/cap-1002/.
- Mcdonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [Internet]. 2022. Available from: www.thelancet.com.
- Rüegg U. Tamoxifen in Duchenne muscular dystrophy – promising first results. Neuromuscul Disord. 2021;31(9):801–802. Elsevier Ltd.
- Tamoxifen IP. Fails to show efficacy in Duchenne patients in Phase 3 trial [Internet]. 2021 [cited 2022 Jul 6]. Available from: https://musculardystrophynews.com/news/tamoxifen-fails-efficacy-goal-phase-3-trial-duchenne-muscular-dystrophy/.
- Birnbaum F, Eguchi A, Pardon G, et al. Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med. 2022;7(1):7.
- Wexler M. FDA Places Pamrevlumab for DMD on fast track. 2021 [cited 2022 Jul 6]; Available from: https://musculardystrophynews.com/news/pamrevlumab-fda-fast-track-designation-duchenne-muscular-dystrophy/.
- Elangkovan N, Dickson G, Jaiswal J. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8(s2):S303–S316. NLM (Medline).
- Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464–488. Cell Press.
- Wilton-Clark H, Yokota T. Antisense and gene therapy options for Duchenne muscular dystrophy arising from mutations in the N-Terminal hotspot. Genes (Basel). 2022;13(2):257. MDPI.
- Asher DR, Thapa K, Dharia SD, et al. Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20(3):263–274. Taylor and Francis Ltd.
- Wexler M. Phase 3 trial of pfizer’s gene therapy expected to open in US in June. 2022 May 3 [cited 2022 Jun 22]; Available from: https://musculardystrophynews.com/2022/05/03/phase-3-trial-of-pfizers-gene-therapy-expected-to-open-in-us-in-june/.
- Gomes MJ, Martinez PF, Pagan LU, et al. Skeletal muscle aging: influence of oxidative stress and physical exercise. Oncotarget. 2017;8(12):20428–20440.
- Garegnani L, Hyland M, Roson Rodriguez P, et al. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline. Cochrane database of systematic reviews. 2021;(12):Article no. CD013720.
- LoMauro A, D’Angelo MG, Aliverti A. Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag. 2015;11:1475–1488.
- Grages SM, Bell M, Berlau DJ. New and emerging pharmacotherapy for Duchenne muscular dystrophy: a focus on synthetic therapeutics. Expert Opin Pharmacother. 2020;21(7):841–851. Taylor and Francis Ltd.
- Stewart J. FDA Rejects New Drug application for translarna to treat DMD [Internet]. 2017 [cited 2022 Jul 6]. Available from: https://musculardystrophynews.com/news/dmd-fda-rejects-new-drug-application-translarna/.
- Keown A. PTC ready to take another shot at FDA approval of DMD drug, translarna. 2022.
- Pickar-Oliver A, Gough V, Bohning JD, et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther. 2021;29(11):3243–3257.
- Happi Mbakam C, Lamothe G, Tremblay G, et al. CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy. Neurotherapeutics. 2022;19(3):931–941.
- Hara M, Yuasa S, Shimoji K, et al. G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation. J Exp Med. 2011;208(4):715–727.
- Hayashiji N, Yuasa S, Miyagoe-Suzuki Y, et al. G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy. Nat Commun. 2015;6(6745).
- Sienkiewicz D, Kulak W, Okurowska-Zawada B, et al. Efficacy and the safety of granulocyte colony-stimulating factor treatment in patients with muscular dystrophy: a non-randomized clinical trial. Front Neurol. 2017;8:8.
- Previtali SC, Gidaro T, Díaz-Manera J, et al. Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with Duchenne muscular dystrophy. Pharmacol Res. 2020;159:104999.
- Ghaleh B, Barthélemy I, Wojcik J, et al. Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs. Int J Cardiol. 2020;312:89–95.
- Soblechero-Martín P, López-Martínez A, de la Puente-Ovejero L, et al. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol. 2021;47(6):711–723.
- Idrus A. Summit dumps ezutromid after phase 2 Duchenne fail [Internet]. 2018 [cited 2022 Jul 6]. Available from: https://www.fiercebiotech.com/summit-dumps-ezutromid-after-phase-2-duchenne-fail.
- Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15(4):840–848. Springer New York LLC.
- Institute for clinical and economic review (ICER). Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value final evidence report [Internet]. Available from: https://icer-review.org/programs/new-england-cepac/.